GOLDSMITH MARK A 4

What Happened

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines (RVMD), sold 10,020 shares on June 16, 2026 in an open-market transaction for a total of $1,564,310. The weighted-average price reported was $156.12 per share.
• The sale was executed pursuant to a Rule 10b5-1 plan to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units (RSUs).

Key Details

• Transaction date: 2026-06-16; weighted-average price: $156.12; total proceeds: $1,564,310.
• Price range across multiple trades: $156.1105 to $156.8250 (weighted average reported; reporting person can provide individual trade details on request).
• Purpose/footnote: F1 — sale made under a 10b5-1 instruction adopted May 31, 2023 to cover tax withholding on RSU vesting. F2 — multiple trades; F3 — filing notes 182,938 RSUs included; F4 — includes 652 ESPP shares; F5–F7 — certain shares held in family revocable trusts.
• Filing: Form 4 filed on June 18, 2026 reporting the June 16 transaction — appears timely (Form 4 required within two business days).

Context

• This was a sale to satisfy tax-withholding obligations associated with RSU vesting (a routine, pre-arranged 10b5-1 sale), which is generally considered administrative rather than a direct signal of the insider’s view of the company.
• Proceeds were roughly $1.56M. For retail investors, purchases often carry stronger informational weight than withholding sales; this filing documents insider liquidity tied to compensation events rather than an opportunistic open-market sale.